Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2006-001300-37-DE
EUCTR2006-001300-37-DEActive, not recruitingNot Applicable

Immunogenicity and reactogenicity of the trivalent influenza subunit vaccine Influvac® for the season 2006/2007. An open, baseline-controlled study in two groups of healthy subjects: adult subjects greater than or equal to 18 and less than or equal 60 years and elderly subjects greater than or equal to 61 years of age. - Influvac annual update 2006

Solvay Pharmaceuticals B.V.0 sites120 target enrollmentStarted: April 26, 2006Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
120
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Signed and dated informed consent.
  • •2. Healthy and aged =18 and = 60 years or = 61 years of age.
  • •3. Mental health must be good enough to understand the study and the informed consent form and to fill in the questionnaire.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •1. Known to be allergic to eggs, chicken protein, gentamicin or any other constituent of the vaccine.
  • •2. Having fever and/or presenting with an acute infectious episode of the upper and/or lower respiratory airways.
  • •3. Having experienced a documented serious systemic reaction after previous influenza vaccination.
  • •4. Having an auto-immune disorder (e.g. RA, SLE, auto-immune thyroid disorders) or other disorders affecting the immune system, taking immunosuppressive medication (such as systemic corticosteroids) including the four weeks preceding the start of the study (date of informed consent), or having a disease in a terminal stage.
  • •5. Having received vaccination against influenza within the previous six months before Visit 1.
  • •Exclusion criteria only for female subjects aged =18 and = 60 years and of childbearing potential:
  • •6. Pregnancy (positive urine pregnancy test on Day 1) or breastfeeding.
  • •7. Absence of use of a medically accepted method of birth control (i.e. oral contraceptive, Intra Uterine Device, double barrier method).
  • •The rationale for the above exclusion criteria 1 and 3 is that of safety; exclusion criteria 2, 4 and 5 are necessary for eligibility, as they prevent interference with this study’s primary objective (immunogenicity against hemagglutinin of the specified strains of influenza ; also see section 7.8); and although allowed as per label, exclusion criteria 6 and 7 are standard for these clinical studies due to administrative reasons.

Investigators

Sponsor
Solvay Pharmaceuticals B.V.

Similar Trials

Active, not recruiting
Not Applicable
Immunogenicity and reactogenicity of the trivalent virosomal influenza vaccine Invivac® for the season 2005/2006. An open, baseline controlled study in twogroups of healthy subjects: adult subjects aged = 18 and =60 years and elderly subjects = 61 years of age.(Extension to protocol S206.3.010) - InvivacProphylaxis of influenza in adults and the elderly, especially in those who run an increased risk of associated complications.
EUCTR2005-003791-38-DESolvay Pharmaceuticals B.V.120
Active, not recruiting
Not Applicable
Immunogenicity and reactogenicity of the trivalent virosomal influenza vaccine Invivac® for the season 2005/2006. An open, baseline controlled study in two groups of healthy subjects: adult subjects aged =18 and =60 years and elderly subjects =61 years of age. - Invivac
EUCTR2005-000341-11-DESolvay Pharmaceuticqals B.V.120
Active, not recruiting
Not Applicable
Immunogenicity and reactogenicity of the trivalent influenzasubunit vaccine Influvac® for the season 2006/2007. An open,baseline-controlled study in two groups of healthy subjects:adult subjects greater than or equal to 18 and less than or equal 60 years and elderly subjects greater than or equal to 61 yearsof age. - Influvac annual update 2006Prophylaxis of influenza, especially in those who run an increased risk of associated complications.
EUCTR2006-001300-37-BESolvay Pharmaceuticals B.V.120
Active, not recruiting
Not Applicable
Immunogenicity and reactogenicity of the trivalent influenza subunit vaccine Influvac® for the season 2007/2008. An open, baseline-controlled multi-centre study in two groups of healthy subjects: Adult subjects aged greater than or equal to 18 and less than or equal to 60 years and elderly subjects greater than 61 years of age. - Influvac Annual Update 2007/2008
EUCTR2007-000875-40-DESolvay Pharmaceuticals B.V.120
Active, not recruiting
Phase 1
Immunogenicity and reactogenicity of the trivalent influenza subunit vaccine Influvac® for the season 2007/2008. An open, baseline-controlled multi-centre study in two groups of healthy subjects: Adult subjects aged greater than or equal to 18 and less than or equal to 60 years and elderly subjects greater than 61 years of age. - Influvac Annual Update 2007/2008Prophylaxis of influenza.MedDRA version: 9.1Level: HLTClassification code 10022005Term: Influenza viral infections
EUCTR2007-000875-40-BESolvay Pharmaceuticals B.V.120